Profile data is unavailable for this security.
About the company
Finch Therapeutics Group, Inc. is a microbiome technology company with a portfolio of intellectual property and microbiome assets. It is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. It has an intellectual property estate, including more than 113 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. Its assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.
- Revenue in USD (TTM)0.00
- Net income in USD-16.28m
- Incorporated2017
- Employees18.00
- LocationFinch Therapeutics Group Inc75 State Street, Suite 100BOSTON 02109United StatesUSA
- Phone+1 (617) 229-6499
- Fax+1 (302) 636-5454
- Websitehttps://finchtherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Panbela Therapeutics Inc | 0.00 | -27.26m | 1.87m | 7.00 | -- | -- | -- | -- | -20.38 | -20.38 | 0.00 | -0.6563 | 0.00 | -- | -- | 0.00 | -201.94 | -215.89 | -809.38 | -476.38 | -- | -- | -- | -- | -- | -161.79 | 4.16 | -- | -- | -- | 27.68 | -- | -- | -- |
| Windtree Therapeutics Inc | 0.00 | -5.96m | 1.91m | 15.00 | 0.1738 | 0.1065 | -- | -- | 18.53 | 18.53 | 0.00 | 30.23 | 0.00 | -- | -- | 0.00 | -18.26 | -44.51 | -20.72 | -48.38 | -- | -- | -- | -94,533.34 | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -- | -- |
| CanaQuest Medical Corp | 0.00 | -803.71k | 1.92m | -- | -- | -- | -- | -- | -0.0511 | -0.0511 | 0.00 | -0.0368 | 0.00 | -- | -- | -- | -1,084.38 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 57.42 | -- | -- | -- |
| Galmed Pharmaceuticals Ltd | 0.00 | -6.36m | 1.97m | 3.00 | -- | 0.1461 | -- | -- | -2.83 | -2.83 | 0.00 | 2.12 | 0.00 | -- | -- | 0.00 | -43.37 | -45.06 | -51.38 | -50.79 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.31 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -27.31m | 2.13m | 40.00 | -- | 0.0576 | -- | -- | -98.49 | -97.90 | 0.00 | 9.06 | 0.00 | -- | -- | 0.00 | -103.85 | -47.16 | -134.86 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
| AgriFORCE Growing Systems Ltd | 16.28k | -13.34m | 2.13m | 7.00 | -- | 0.2068 | -- | 130.98 | -10.78 | -10.78 | 0.0039 | 0.396 | 0.0009 | -- | 0.443 | 2,325.71 | -74.39 | -78.95 | -100.77 | -109.86 | 16.58 | -- | -81,946.25 | -243,182.50 | 0.8186 | -1.30 | 0.1913 | -- | -- | -- | 8.85 | -- | 48.61 | -- |
| Finch Therapeutics Group Inc | 0.00 | -16.28m | 2.17m | 18.00 | -- | 0.1139 | -- | -- | -10.14 | -10.14 | 0.00 | 11.86 | 0.00 | -- | -- | -- | -25.22 | -- | -28.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| InMed Pharmaceuticals Inc | 5.63m | -6.08m | 2.20m | 13.00 | -- | 0.1503 | -- | 0.3907 | -1.23 | -1.23 | 0.9284 | 1.75 | 0.4006 | 2.71 | 29.77 | -- | -43.26 | -88.10 | -50.03 | -104.19 | 39.20 | -- | -108.01 | -1,066.11 | 5.80 | -- | 0.00 | -- | 279.60 | -- | 57.27 | -- | 29.56 | -- |
| Axim Biotechnologies Inc | 85.35k | -5.59m | 2.22m | 6.00 | -- | -- | -- | 25.95 | -0.0249 | -0.0249 | 0.0003 | -0.0268 | 0.0214 | -- | -- | 14,225.00 | -140.13 | -154.34 | -- | -390.73 | -- | -- | -6,548.75 | -36,362.71 | -- | -1.16 | -- | -- | 345.05 | -27.38 | -29.10 | -- | -- | -- |
| Eloxx Pharmaceuticals Inc | 0.00 | -20.48m | 2.28m | 18.00 | -- | -- | -- | -- | -9.06 | -9.06 | 0.00 | -6.53 | 0.00 | -- | -- | 0.00 | -124.43 | -115.27 | -- | -155.33 | -- | -- | -- | -- | -- | -16.69 | -- | -- | -- | -- | 45.95 | -- | -22.56 | -- |
| Agile Therapeutics Inc | 21.50m | -7.79m | 2.29m | 19.00 | -- | -- | -- | 0.1065 | -3.65 | -3.65 | 6.98 | -1.51 | 1.63 | 2.90 | 5.42 | 1,131,316.00 | -59.25 | -94.24 | -- | -142.62 | 59.73 | -- | -36.26 | -513.50 | 0.3843 | -- | -- | -- | 80.02 | -- | 43.08 | -- | -- | -- |
| cbdMD Inc | 21.58m | -25.65m | 2.36m | 52.00 | -- | 0.6028 | -- | 0.1094 | -19.96 | -19.96 | 9.27 | 1.01 | 0.8949 | 2.09 | 21.27 | 415,039.60 | -89.78 | -38.59 | -118.26 | -41.50 | 62.70 | 63.80 | -100.33 | -87.98 | 0.6107 | -3.01 | 0.4668 | -- | -31.77 | 120.91 | 63.64 | -- | -4.95 | -- |
| Tharimmune Inc | 0.00 | -8.89m | 2.44m | 2.00 | -- | 0.3457 | -- | -- | -111.65 | -111.65 | 0.00 | 8.97 | 0.00 | -- | -- | 0.00 | -130.60 | -- | -173.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
| Veritas Farms Inc | 730.65k | -6.15m | 2.46m | 17.00 | -- | 12.14 | -- | 3.36 | -0.1319 | -0.1319 | 0.0136 | 0.0013 | 0.0877 | 0.8064 | 7.80 | 42,979.41 | -69.02 | -72.11 | -123.21 | -93.59 | -220.09 | 24.07 | -787.27 | -177.79 | 0.1392 | -5.56 | 0.95 | -- | -63.42 | -0.9427 | 23.68 | -- | -52.93 | -- |
Data as of Jun 27 2024. Currency figures normalised to Finch Therapeutics Group Inc's reporting currency: US Dollar USD
6.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Susquehanna Investment Group LLCas of 31 Mar 2024 | 59.03k | 3.68% |
| Lake Street Advisors Group LLCas of 31 Mar 2024 | 21.21k | 1.32% |
| Ikarian Capital LLCas of 31 Mar 2024 | 6.89k | 0.43% |
| Geode Capital Management LLCas of 30 Apr 2024 | 6.40k | 0.40% |
| Tower Research Capital LLCas of 31 Mar 2024 | 4.16k | 0.26% |
| Aperture Investors LLCas of 30 Sep 2021 | 3.96k | 0.25% |
| Bleichroeder LPas of 31 Mar 2024 | 971.00 | 0.06% |
| UBS Securities LLCas of 31 Mar 2024 | 110.00 | 0.01% |
| RBC Dominion Securities, Inc.as of 31 Mar 2024 | 27.00 | 0.00% |
| Guggenheim Funds Investment Advisors LLCas of 29 Feb 2024 | 1.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
